Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.

Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.

Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.

Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment Trial to initiate this quarter with data anticipated in 2021 Convenient oral alternative to injectable epinephrine NORTH HAVEN, Conn. and NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) --...